Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (3)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

October 23, 2020 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is inter alia to enhance the company’s financial position ahead of negotiating a deal pertaining to its lead product HyNap-Dasa and to continue to expand the company’s product portfolio.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson and Linnea Petersson.

Related

Vinge has advised Montrose by Carnegie AB on its application for authorisation to conduct securities business

 Vinge has successfully advised Montrose by Carnegie AB in connection with its application to the Swedish Financial Supervisory Authority for authorisation to conduct securities business. The authorisation was granted by the Swedish Financial Supervisory Authority on 2 July 2026.
August 12, 2026

Vinge advises Mjällby AIF on the transfer of Elliot Stroud to Hull City AFC

 Vinge has advised reigning Allsvenskan champions Mjällby AIF in connection with the transfer of Swedish international Elliot Stroud to Premier League club Hull City AFC.
August 10, 2026

Vinge advises Altor on its public offer for Sleep Cycle

 Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026